Voxzogo Market Report 2026

Voxzogo Market Overview

• The Voxzogo market growth in the historic period has been driven by improved genetic testing for achondroplasia, clinical validation of CNP pathway modulation • Market expansion is supported by increasing demand for disease-modifying therapies, expansion of newborn genetic screening programs • Growth Driver: Growing Focus On Rare Diseases And Its Impact On Innovative Treatments • Market Trend: Expanding Indications To Enhance Treatment For Achondroplasia And Skeletal Dysplasias • North America was the largest region in 2025.

What Is Covered Under Voxzogo Market?

Voxzogo (vosoritide) is a biologic drug designed to treat achondroplasia, caused by a genetic mutation in the FGFR3 gene. Voxzogo works by counteracting the effects of FGFR3 by promoting endochondral ossification, the process of bone growth at the growth plates, promoting bone growth by modulating the activity of C-type natriuretic peptide (CNP). The main indications for the voxzogo are growth hormone deficiency, noonan syndrome, achondroplasia, and others. Growth hormone deficiency (GHD) refers to a medical condition characterized by the insufficient production or secretion of growth hormone (GH) by the pituitary gland, a small gland at the base of the brain. The various distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and clinics, and several end users, including pediatrics, adults, and geriatric population.

What Is The Voxzogo Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for disease-modifying therapies, expansion of newborn genetic screening programs, rising investments in rare pediatric drug development, growing focus on personalized medicine, advancements in biologic drug delivery technologies. Major trends in the forecast period include increasing adoption of targeted genetic disorder therapies, rising use of peptide-based growth modulators, growing focus on early intervention for rare diseases, expansion of personalized pediatric treatments, enhanced emphasis on long-term growth outcomes.

Global Voxzogo Market Segmentation

1) By Indication: Growth Hormone Deficiency, Noonan Syndrome, Achondroplasia, Other Rare Disorders 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Clinics 3) By End User: Pediatrics, Adults, Geriatric Population

What Are The Drivers Of The Voxzogo Market?

The growing focus and investment in rare diseases is expected to propel the growth of the voxzogo market going forward. Rare diseases are medical conditions that affect a small percentage of the population, fewer than 200,000 people in a given country. The growing focus and investment in rare diseases is driven by advancements in genetic research, the potential for innovative treatments, and increasing recognition of the unmet medical needs of affected patients. Investment in rare diseases helps voxzogo by fostering the development and accessibility of innovative treatments for conditions like achondroplasia, thereby expanding its market reach and addressing unmet medical needs. For instance, in February 2024, the Government of Canada, a Canada-based government agency, invested $20 million to improve health outcomes of children living with rare diseases. Therefore, growing focus and investment in rare diseases is driving the growth of the voxzogo industry. The rise in personalized medicine is expected to propel the growth of the voxzogo market going forward. Personalized medicine is a medical approach that tailors treatments based on an individual's genetic makeup, lifestyle, and specific health conditions. The rise in personalized medicine is driven by advancements in genomics, increasing precision in treatments, and the growing ability to target diseases based on individual genetic profiles. Voxzogo supports personalized medicine by offering a targeted treatment specifically designed for children with achondroplasia, addressing the unique genetic and biological factors of the condition, thereby exemplifying a tailored approach to improve individual patient outcomes and quality of life. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the US Food and Drug Administration (FDA) granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, the rise in personalized medicine is driving the growth of the voxzogo industry.

Key Players In The Global Voxzogo Market

Major companies operating in the voxzogo market are BioMarin Pharmaceutical Inc.

Global Voxzogo Market Trends and Insights

The key trend in the voxzogo market is focusing on expanding indications to enhance treatment options for patients with achondroplasia. Expanding indications seek to provide improved growth and bone health for patients beyond the current approved age group, such as adolescents and adults with achondroplasia, and potentially for other skeletal dysplasias. For instance, in October 2023, BioMarin Pharmaceutical Inc., a US-based biotechnology company, received Food and Drug Administration approval for Voxzogo (vosoritide) to treat children under five years of age with achondroplasia, expanding its use from the previous indication for children aged five and older. It is specifically designed to increase linear growth in children with achondroplasia who have open growth plates (epiphyses), meaning their bones can still grow. Voxzogo is administered through subcutaneous injections and has been shown to improve height in children receiving the treatment, with the potential for more significant growth benefits when started at a younger age.

Regional Insights

North America was the largest region in the voxzogo market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Voxzogo Market?

The voxzogo market consists of sales of injection delivery devices, supportive therapies, genetic testing kits, and growth monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Voxzogo Market Report 2026?

The voxzogo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the voxzogo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.